|
1
|
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
|
N Engl J Med
|
2011
|
12.45
|
|
2
|
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
|
N Engl J Med
|
2015
|
5.07
|
|
3
|
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
|
N Engl J Med
|
2015
|
4.97
|
|
4
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
|
Lancet Oncol
|
2013
|
3.87
|
|
5
|
Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
|
Hum Pathol
|
2006
|
2.92
|
|
6
|
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
|
Lancet Oncol
|
2012
|
2.48
|
|
7
|
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.
|
J Clin Oncol
|
2013
|
2.26
|
|
8
|
Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.
|
J Clin Oncol
|
2013
|
1.96
|
|
9
|
Brain metastases in breast cancer: prognostic factors and management.
|
Breast Cancer Res Treat
|
2007
|
1.92
|
|
10
|
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
|
J Nucl Med
|
2013
|
1.82
|
|
11
|
Leptomeningeal carcinomatosis in gastric cancer.
|
J Neurooncol
|
2004
|
1.71
|
|
12
|
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
|
Breast Cancer Res Treat
|
2007
|
1.68
|
|
13
|
Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer.
|
Ann Thorac Surg
|
2012
|
1.56
|
|
14
|
Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus.
|
Phytomedicine
|
2013
|
1.26
|
|
15
|
Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
|
Eur J Cancer
|
2007
|
1.16
|
|
16
|
Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC).
|
Breast Cancer Res Treat
|
2008
|
1.12
|
|
17
|
Intramedullary spinal cord metastases: a single-institution experience.
|
J Neurooncol
|
2007
|
1.10
|
|
18
|
Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.
|
Clin Cancer Res
|
2008
|
1.09
|
|
19
|
Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx.
|
J Nucl Med
|
2007
|
1.01
|
|
20
|
Synergistic effect of emodin in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus.
|
Pharm Biol
|
2010
|
1.01
|
|
21
|
Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
|
Cancer Chemother Pharmacol
|
2012
|
0.98
|
|
22
|
Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
|
J Transl Med
|
2011
|
0.97
|
|
23
|
ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
|
Eur J Cancer
|
2007
|
0.97
|
|
24
|
Retrievable covered nitinol stents: experiences in 108 patients with malignant esophageal strictures.
|
J Vasc Interv Radiol
|
2002
|
0.97
|
|
25
|
Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy.
|
J Breast Cancer
|
2012
|
0.96
|
|
26
|
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
|
Breast Cancer Res Treat
|
2010
|
0.94
|
|
27
|
Finding and characterizing mammary analogue secretory carcinoma of the salivary gland.
|
Korean J Pathol
|
2013
|
0.93
|
|
28
|
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
|
Eur J Cancer
|
2013
|
0.92
|
|
29
|
A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer.
|
Breast Cancer Res Treat
|
2006
|
0.92
|
|
30
|
Comparison of temporary and permanent stent placement with concurrent radiation therapy in patients with esophageal carcinoma.
|
J Vasc Interv Radiol
|
2005
|
0.92
|
|
31
|
Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience.
|
Korean J Intern Med
|
2007
|
0.91
|
|
32
|
Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma.
|
Ann Surg Oncol
|
2011
|
0.91
|
|
33
|
Food impaction after expandable metal stent placement: experience in 1,360 patients with esophageal and upper gastrointestinal tract obstruction.
|
J Vasc Interv Radiol
|
2011
|
0.91
|
|
34
|
Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.90
|
|
35
|
18 F-fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: a retrospective cohort study.
|
J Surg Oncol
|
2012
|
0.90
|
|
36
|
Covered metallic stent placement in the management of cervical esophageal strictures.
|
J Vasc Interv Radiol
|
2007
|
0.88
|
|
37
|
Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer.
|
J Breast Cancer
|
2012
|
0.88
|
|
38
|
Prediction of posttreament significant body weight loss and its correlation with disease-free survival in patients with oral squamous cell carcinomas.
|
Nutr Cancer
|
2013
|
0.88
|
|
39
|
Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer.
|
BMC Cancer
|
2014
|
0.87
|
|
40
|
Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.86
|
|
41
|
Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses.
|
Transfusion
|
2004
|
0.85
|
|
42
|
Management of tracheomediastinal fistula using a self-expanding metallic tracheal stent.
|
Cardiovasc Intervent Radiol
|
2009
|
0.85
|
|
43
|
The mechanism of antimicrobial activity of sophoraflavanone B against methicillin-resistant Staphylococcus aureus.
|
Foodborne Pathog Dis
|
2014
|
0.84
|
|
44
|
Membrane degradation of covered stents in the upper gastrointestinal tract: frequency and clinical significance.
|
J Vasc Interv Radiol
|
2008
|
0.84
|
|
45
|
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
|
Cancer Chemother Pharmacol
|
2011
|
0.83
|
|
46
|
Clinical value of cyclooxygenase-2 expression in human breast carcinoma.
|
Cancer Res Treat
|
2004
|
0.83
|
|
47
|
Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram.
|
Neuro Oncol
|
2012
|
0.82
|
|
48
|
Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.
|
J Korean Med Sci
|
2004
|
0.82
|
|
49
|
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
|
Breast Cancer Res Treat
|
2015
|
0.82
|
|
50
|
Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience.
|
Cancer Chemother Pharmacol
|
2013
|
0.82
|
|
51
|
Clinical characteristics and prognostic factors of adenoid cystic carcinoma of the head and neck.
|
Laryngoscope
|
2013
|
0.81
|
|
52
|
Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
|
Jpn J Clin Oncol
|
2007
|
0.81
|
|
53
|
Palliative treatment of unresectable esophagogastric junction tumors: balloon dilation combined with chemotherapy and/or radiation therapy and metallic stent placement.
|
J Vasc Interv Radiol
|
2008
|
0.81
|
|
54
|
Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
|
Ann Surg Oncol
|
2014
|
0.81
|
|
55
|
Collection of peripheral blood progenitor cells: analysis of factors predicting the yields.
|
Transfus Apher Sci
|
2003
|
0.80
|
|
56
|
Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study.
|
Cancer Chemother Pharmacol
|
2013
|
0.80
|
|
57
|
Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial.
|
Int J Hematol
|
2002
|
0.80
|
|
58
|
Noncancer-Related Health Events and Mortality in Head and Neck Cancer Patients After Definitive Radiotherapy: A Prospective Study.
|
Medicine (Baltimore)
|
2016
|
0.80
|
|
59
|
Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine.
|
Jpn J Clin Oncol
|
2011
|
0.80
|
|
60
|
Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.
|
Eur J Nucl Med Mol Imaging
|
2011
|
0.80
|
|
61
|
Polytetrafluoroethylene-covered retrievable expandable nitinol stents for malignant esophageal obstructions: factors influencing the outcome of 270 patients.
|
AJR Am J Roentgenol
|
2012
|
0.80
|
|
62
|
Gomisin N has anti-allergic effect and inhibits inflammatory cytokine expression in mouse bone marrow-derived mast cells.
|
Immunopharmacol Immunotoxicol
|
2011
|
0.79
|
|
63
|
The mechanism of action of sanguinarine against methicillin-resistant Staphylococcus aureus.
|
J Toxicol Sci
|
2011
|
0.79
|
|
64
|
The efficacy of high-dose melphalan with autologous peripheral blood stem cell transplantation in patients with multiple myeloma.
|
Yonsei Med J
|
2003
|
0.79
|
|
65
|
Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.
|
Breast Cancer Res Treat
|
2011
|
0.79
|
|
66
|
Distant metastases and survival prediction in head and neck squamous cell carcinoma.
|
Otolaryngol Head Neck Surg
|
2012
|
0.79
|
|
67
|
Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.
|
Jpn J Clin Oncol
|
2010
|
0.79
|
|
68
|
p16 immunohistochemistry alone is a better prognosticator in tonsil cancer than human papillomavirus in situ hybridization with or without p16 immunohistochemistry.
|
Acta Otolaryngol
|
2012
|
0.79
|
|
69
|
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
|
Oncol Rep
|
2005
|
0.78
|
|
70
|
Alternative therapy and abnormal liver function during adjuvant chemotherapy in breast cancer patients.
|
J Korean Med Sci
|
2004
|
0.78
|
|
71
|
Intratumor Textural Heterogeneity on Pretreatment (18)F-FDG PET Images Predicts Response and Survival After Chemoradiotherapy for Hypopharyngeal Cancer.
|
Ann Surg Oncol
|
2014
|
0.78
|
|
72
|
Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
|
J Surg Oncol
|
2013
|
0.78
|
|
73
|
Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.
|
Tumour Biol
|
2015
|
0.78
|
|
74
|
F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma.
|
Oral Oncol
|
2006
|
0.78
|
|
75
|
Ethnicity and breast cancer research.
|
Lancet
|
2008
|
0.78
|
|
76
|
Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
|
Breast Cancer
|
2011
|
0.78
|
|
77
|
Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.78
|
|
78
|
Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.78
|
|
79
|
Laryngeal edema after radiotherapy in patients with squamous cell carcinomas of the larynx and hypopharynx.
|
Oral Oncol
|
2012
|
0.78
|
|
80
|
Clinical significance of pretreatment metabolic tumor volume and total lesion glycolysis in hypopharyngeal squamous cell carcinomas.
|
J Surg Oncol
|
2014
|
0.78
|
|
81
|
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
|
Breast Cancer Res Treat
|
2011
|
0.78
|
|
82
|
Can concurrent chemoradiotherapy replace surgery and postoperative radiation for locally advanced stage III/IV tonsillar squamous cell carcinoma?
|
Anticancer Res
|
2013
|
0.78
|
|
83
|
Synergistic effect of tetrandrine and ethidium bromide against methicillin-resistant Staphylococcus aureus (MRSA).
|
J Toxicol Sci
|
2011
|
0.77
|
|
84
|
The mechanism of antibacterial activity of tetrandrine against Staphylococcus aureus.
|
Foodborne Pathog Dis
|
2012
|
0.77
|
|
85
|
S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?
|
Expert Rev Anticancer Ther
|
2010
|
0.77
|
|
86
|
Clinical usefulness of the hematopoietic progenitor cell counts in predicting the optimal timing of peripheral blood stem cell harvest.
|
J Korean Med Sci
|
2003
|
0.77
|
|
87
|
ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.
|
Korean J Intern Med
|
2006
|
0.77
|
|
88
|
Importance of FOXP3 in prognosis and its relationship with p16 in tonsillar squamous cell carcinoma.
|
Anticancer Res
|
2013
|
0.77
|
|
89
|
Anti-allergic effects of sinomenine by inhibition of prostaglandin D₂ and leukotriene C₄ in mouse bone marrow-derived mast cells.
|
Immunopharmacol Immunotoxicol
|
2010
|
0.77
|
|
90
|
Evaluation of the incidence of esophageal complications associated with balloon dilation and their management in patients with malignant esophageal strictures.
|
AJR Am J Roentgenol
|
2012
|
0.77
|
|
91
|
Can response to induction chemotherapy be a predictive marker for ultimate outcome in hypopharyngeal cancer?
|
Otolaryngol Head Neck Surg
|
2011
|
0.76
|
|
92
|
Temporary stent placement with concurrent chemoradiation therapy in patients with unresectable oesophageal carcinoma: is there an optimal time for stent removal?
|
Eur Radiol
|
2013
|
0.76
|
|
93
|
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).
|
Eur J Cancer
|
2012
|
0.76
|
|
94
|
Early evaluation of the response to radiotherapy of patients with squamous cell carcinoma of the head and neck using 18FDG-PET.
|
Oral Oncol
|
2005
|
0.76
|
|
95
|
Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines.
|
Breast
|
2005
|
0.75
|
|
96
|
Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients.
|
Cancer Res Treat
|
2006
|
0.75
|
|
97
|
High-dose chemotherapy of cyclophosphamide, thiotepa and carboplatin (CTCb) followed by autologous stem-cell transplantation as a consolidation for breast cancer patients with 10 or more positive lymph nodes: a 5-year follow-up results.
|
Cancer Res Treat
|
2005
|
0.75
|
|
98
|
Double autologous stem cell transplantation for multiple myeloma: a Korean single center study.
|
Korean J Intern Med
|
2005
|
0.75
|
|
99
|
Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report.
|
J Breast Cancer
|
2011
|
0.75
|
|
100
|
High-dose chemotherapy of cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by autologous stem-cell transplantation for metastatic breast cancer patients: a 6-year follow-up result.
|
Cancer Res Treat
|
2005
|
0.75
|
|
101
|
Combination Therapy of Sophoraflavanone B against MRSA: In Vitro Synergy Testing.
|
Evid Based Complement Alternat Med
|
2013
|
0.75
|
|
102
|
The anti-inflammatory effect of Cheongseoikki-tang ethanol extract on allergic reactions mediated by bone marrow-derived mast cells.
|
Chin J Integr Med
|
2013
|
0.75
|
|
103
|
Radiation therapy with UFT and low dose weekly cisplatin for nasopharyngeal carcinoma.
|
Auris Nasus Larynx
|
2004
|
0.75
|
|
104
|
Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience.
|
Cancer Chemother Pharmacol
|
2014
|
0.75
|
|
105
|
Translation and validation of Korean Functional Assessment of Cancer Therapy-Esophageal (FACT-E) scale with squamous cell carcinoma and chemoradiation-only patients.
|
Qual Life Res
|
2011
|
0.75
|
|
106
|
Efficacy of neoadjuvant chemoradiotherapy in resectable esophageal squamous cell carcinoma--a single institutional study.
|
Acta Oncol
|
2003
|
0.75
|
|
107
|
In vitro potentiation of ampicillin, oxacillin, norfloxacin, ciprofloxacin, and vancomycin by sanguinarine against methicillin-resistant Staphylococcus aureus.
|
Foodborne Pathog Dis
|
2011
|
0.75
|
|
108
|
Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: a multicenter, cross-sectional study.
|
Asia Pac J Clin Oncol
|
2012
|
0.75
|
|
109
|
Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients.
|
Breast Cancer Res Treat
|
2014
|
0.75
|
|
110
|
Reply: 18F-fluoroestradiol positron emission tomography to predict response to neoadjuvant treatment in luminal breast cancer.
|
J Nucl Med
|
2016
|
0.75
|